E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001896 |
E.1.2 | Term | Alzheimer's disease |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to assess the cerebrospinal fluid (CSF) pharmacodynamic (PD) effect of LY2886721 doses in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild AD compared to placebo, measured by change of CSF Aβ1 40 and Aβ1 42 concentrations from baseline to Week 12 and Week 26. |
|
E.2.2 | Secondary objectives of the trial |
To assess safety and tolerability of LY2886721 over 26 weeks.
To compare cerebral vasogenic edema (ARIA-E) and cerebral microhemorrhage (ARIA-H) using fluid attenuation inversion recovery (FLAIR) and T2*w MRI associated with different doses of LY2886721 treatment or placebo
To assess the plasma PD effect of different LY2886721 doses compared to placebo, measured by change of plasma Aβ1-40 & Aβ1-42
concentrations from baseline to Week 12 and 26.
To assess the effect of 2 doses of LY2886721 compared to placebo on the cognitive and behavioral symptoms of AD measured by
Neuropsychological Test Battery (NTB), AD Assessment Scale – Cognitive subscale (ADAS-Cog), Mini Mental State Examination (MMSE), &
Neuropsychiatric Inventory (NPI).
To assess the effect of 2 doses of LY2886721 compared to placebo on the global rating of symptoms of AD measured by the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB).
To assess change from baseline to Week 12 and 26 for cSF tau and ptau181. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
[1] Present with MCI due to AD or mild AD based on the disease diagnostic criteria
[2] Are men or postmenopausal women, at least 55 years of age. Postmenopausal women are defined as women who have had a hysterectomy and/or bilateral oophorectomy; or who have been amenorrheic for at least 2 years. Men are required to use an approved barrier method of contraception if their partners are pregnant, or of childbearing potential and not using approved contraceptive methods.
[3] Have a reliable caregiver/study informant who provides a separate written informed consent to participate and who has sufficient contact with the patient to provide information about the patient’s daily activities. The caregiver/study informant must be able to communicate with site personnel and in the investigator’s opinion must have adequate literacy to complete the protocol-specified questionnaires. If a caregiver/study informant cannot continue, 1 replacement is allowed.
[4] Have adequate vision and hearing for neuropsychological testing in the opinion of the investigator
[5] Have adequate premorbid literacy in the investigator’s opinion to complete the required psychometric tests
[6] Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site.
Disease Diagnostic Criteria
Patients with MCI due to AD or mild AD will be selected according to the following criteria:
- Gradual and progressive change in memory function reported by patient or caregiver/study informant over more than 6 months.
- Objective evidence of significantly impaired episodic memory characteristic of hippocampal dysfunction on testing: Free and Cued Selective Reminding Test with Immediate Recall (FCSRT – IR): ≤16 for free recall or ≤40 for total recall. The episodic memory impairment can be isolated or associated with other cognitive changes at the onset of AD or as AD advances.
- Clinical Dementia Rating Scale (CDR) = 0.5 or 1, memory box score ≥0.5
- Mini Mental State Examination (MMSE) 20 to 30
- florbetapir F18 scan positive for the presence of Aβ(based on central review) |
|
E.4 | Principal exclusion criteria |
•Participant in another drug or device study
•Have a history of frontotemporal dementia, Lewy body disease, vascular dementia, Huntington's disease or Parkinson's disease, progressive supranuclear palsy (PSNP) or other movement disorder
•Participants are not on a stable standard of care (acetylcholinesterase inhibitors, memantine) initiated less than two months prior to entry or have less than 4 weeks of stable therapy. Note: Stable standard of care is allowed
•Have had a serious infectious disease affecting the brain in the past 5 years
•Have had a serious or repeat head injury
•Have significant retinal impairment or disease
•Have had a stroke or other circulation problems that are affecting your current health
•Have had a positron emission tomography (PET) scan in the past 6 months
•Have had a seizure
•Have major depressive disorder (participation is allowed if depressive symptoms are treated with stabile administration of antidepressants) or another mental illness such as schizophrenia or bipolar disorder
•History of alcohol or drug abuse
•Have asthma, chronic obstructive pulmonary disease (COPD) or other breathing disease that is not controlled with medicine
•Have human immunodeficiency virus (HIV) or syphilis
•Have any medical condition requiring double and triple anti-platelet treatment (for example, combination of aspirin with Clopidogrel, and/or Cilostazol). Note: single antiplatelet therapy is not an exclusion criteria. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
•Change from baseline to 12 weeks in cerebrospinal fluid (CSF) amyloid beta (Aβ)1-40 and Aβ1-42 concentrations [Time Frame: Baseline, 12 weeks]
•Change from baseline to 26 weeks in cerebrospinal fluid (CSF) amyloid beta (Aβ)1-40 and Aβ1-42 concentrations [Time Frame: Baseline, 26 weeks] |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
•Change from baseline to 12 weeks in cerebrospinal fluid (CSF) amyloid beta (Aβ)1-40 and Aβ1-42 concentrations [Time Frame: Baseline, 12 weeks]
•Change from baseline to 26 weeks in cerebrospinal fluid (CSF) amyloid beta (Aβ)1-40 and Aβ1-42 concentrations [Time Frame: Baseline, 26 weeks] |
|
E.5.2 | Secondary end point(s) |
•Change from baseline in plasma amyloid beta (Aβ)1-40 and Aβ1-42 concentrations
•Change from baseline to 26 weeks in Neuropsychological Test Battery (NTB)
•Change from baseline to 26 weeks in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
•Change from baseline to 26 weeks in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
•Change from baseline to 26 weeks in Mini Mental State Examination (MMSE)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
•Change from baseline in plasma amyloid beta (Aβ)1-40 and Aβ1-42 concentrations [Time Frame: Baseline, 12 weeks, 26 weeks ]
•Change from baseline to 26 weeks in NTB [Time Frame: Baseline, 26 weeks]
•Change from baseline to 26 weeks in ADAS-Cog [Time Frame: Baseline, 26 weeks ]
•Change from baseline to 26 weeks in the CDR-SB [ Time Frame: Baseline, 26 weeks ]
•Change from baseline to 26 weeks in MMSE [Time Frame: Baseline, 26 weeks ]
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Italy |
Japan |
Netherlands |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |